Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I also would like to know, where Odidi said, that he would take 12$ per share for his company.
About the buyout rumor: You never know. I just remembered, that Odidi said the following about his story with IPCI:
"We had always wanted to make Intellipharmaceutics public and even had applications made for the listing. But then the opportunity to reverse takeover a public company came up and we took it. Of course, that meant dilution of our holdings and going into partnership/ownership with others; but it was for the better. It is better to own a chunk of a big company rather than whole of a small company. One per cent share in a billion dollar company is better than 100 per cent of a million dollar company. This is one thing entrepreneurs should understand!"
Putting this on a possible buyout, it could also happen, that Odidi will exchange IPCI for shares of another company. It is telling, that the rumour also stated, that if the Odidis sell, they would continue to be directors for 5 years. So they could make IPCI a success story, as they wanted, and still be completly save on the financial side. Hopefully we will know more next week.
Drugmakers, allies fight efforts to limit opioid prescriptions
http://www.freep.com/story/news/local/michigan/2016/09/19/drugmakers-fight-limit-opioid-limit/90511940/
At 19:02 somone pushed the share price back to $ 1.85 buying 1 share
http://www.nasdaq.com/de/symbol/ipci/after-hours
Very quiet here, but the company is making great progress. Looks good in Chile, the lithium market is growing and growing, and the company gets a lot of publicity (see e.g. interviews with BBC and MNBC).
doogdilinger, any insights from your friend who attended the presentation?
Kirin Smith from the IR answered me, that IPCI was not the first to file on any dosis for Seroquel.
Two interesting articles about Isa Odidi, IPCI's CEO:
"Prof. Odidi joins Global Leadership Foundation": insert-text-here
An Interview - "How to make Nigeria’s pharma industry globally competitive": insert-text-here
That's really annoying: Most of the companies at the investor conference make webcast: http://www.meetmax.com/sched/event_35153/~public/conference_keynote.html?event_id=35153 - shame, that IPCI does not stream their presentation.
Samsa, thanks a lot for the explanation!
So, if I understand everything correct, there are two possibilities:
1.) IPCI will file the NDA with PODRAS and will need to raise money for the Phase I to III studies, or
2.) IPCI will file the NDA with PODRAS and announce a partnership with a big upfront payement, that will finance the further needed studies.
I have following question: If IPCI wants to file the NDA for Rexista with (!) PODRAS, will they need to make a Phase III study? Would it make sense now, to file a NDA without PODRAS?
Noodle2, read the annual report.
The delay of the NDA filling leads to the question, how long IPCI still has money. Because the FDA granted a waiver of the $1,187,100 application fee, there is still some money. But what is there actual burn rate now and how long will IPCI cash last?
Okay, thanks for this honest opinion. What do you think about the last financial report. Obviously they need mondery, and the financing is slow (not a good sign), but the numbers in the report were good. What is your opinion about the last financial report?
I do not want to be the party pooper, but one step after another. We all can dream about a buyout in the far future. But in the moment they did not accomplish their already delayed and newly planned filling in August. The PODRAS patent is still under review and their cash resevers are minimal. Not to forget, that they did not managed to make a deal for Keppra.I also hope, that they will not go with empty hands to the investors conference - but it's not impossible that exactly that will happen. Do not get me wrong, I am very bullish for IPCI, but the company has still a long way, to be a buyout-target.
Very quiet here! Any opinion about NSP?
And the next misunderstanding: A friend, who understand more about FDA and the pharma industry explained to me, that IPCI does not need to name a manufacturing partner for the NDA. So a partnership deal is not, what is causing the delay. Hope IPCI is delivering soon.
Sorry, for my mistake, but Odidi's options will not expire at the 10th of September. At the Annual Meeting they were extended for two more years.
The Odidis also have an interested, that something significant happens befor the 10th of September:
The have 2,763,940 options at US$3.62 that expire at Sept. 10, 2016
wimuskyfisherman, your wrote: "In regards to a partner, I feel IPCI has been very clear that they will not partner Rexista until at least after the NDA submission." Where did you read that?
Clarification needed! As I understand it, IPCI needs to name if not a partner, so at least a manufacturer in the USA, right? Naming a manufacturer in this case means nothing else than having a partner for Rexista, or? Can someone please clarfify on this, poiting to the important legal texts? I wrote to the IR on Friday, but did not get an answer. As English is not my mother tongue, I would really appreciate the communities help.
So, they need a manufacturer parnter for a 505(b)(2) NDA!
CMC Information Required in a 505(b)(2) NDA:
"Components, composition, specifications for each component, manufacturer, description of manufacturing and packaging procedures, in-process controls, specifications, and stability"
insert-text-here - see page 7.
And when your read the comments you see, that the author himself has a "small stake".
What do you see about the options?
Thanks, AngeloFoca, for the numbers. I very much appreciate your information sharing!
That will be an interesting day! ASK is down to 1,85 in premarket
Pfizer: FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain http://www.businesswire.com/news/home/20160819005730/en/FDA-Approves-TROXYCA%C2%AE-ER-oxycodone-hydrochloride-naltrexone
There are so many catalysts that can move the SP northward:
- the NDA filling for Rexista this month!
- approval of further doses of Focalin
- the many ANDAs
- and maybe a small but nice deal for Keppra
Thanks to all the amazing informations and thoughts that everyone shares here and that further strengthen my trust in $IPCI!
Good luck to all!
Yesterday's close was very good! The stpck technocal analysis is very positive / bullish: http://www.stockta.com/cgi-bin/analysis.pl?symb=IPCI&cobrand=&mode=stock
Nice green close for the week. Let's hope for good news next weeks. Thanks to everyone for the amazing, interesting posts this week, that made me learn so much! Have a good week-end!
Shared on twitter by IPCI:
http://www.familypracticenews.com/specialty-focus/addiction-medicine/single-article-page/more-states-moving-to-require-payment-for-abuse-deterrent-opioids/3e175096c8de33eea06dc91a09152e24.html
More states moving to require payment for abuse-deterrent opioids
"The Corporation [IPCI] has decided to change its auditor from Deloitte LLP (the "Former Auditor'') to MNP LLP (the "Successor Auditor"). Consequently, on July 27, 2016, the Corporation asked the Former Auditor to resign. The Former Auditor submitted their resignation effective July 27, 2016. Pursuant to the Business Corporations Act (Ontario), the directors are entitled to fill any casual vacancy in the office of the auditor. The Successor Auditor has agreed to its appointment as the Corporation's new auditor."
http://www.intellipharmaceutics.com/secfiling.cfm?filingid=1171843-16-11479&CIK=1474835
For those that do not remember here the CV of Isa Odidi
Dr. Odidi received his B.Sc. Pharmacy (Ahmadu Bello University, Nigeria), M.Sc. Pharmaceutical Technology, Ph.D. Pharmaceutics (University of London), and MBA (Joseph L. Rotman School of Management, University of Toronto), is also a graduate of the Western Executive Program, Ivey School of Business (University of Western Ontario). Dr. Odidi recently awarded Honorary Doctor of Science degree (Honoris causa) University of Benin, Nigeria.
A degree does not make him a great CEO, but he is not "just" a scrientist without knowing how the business works. A part of my decision to invest in IPCI is based on the fact that Odidi is also the CEO.
After all the green days we have a more than reasonable red day and some directly start to lament. About all the comments about IPCIs CEOS I want to mention, that 1.) the decision to go after the ANADs was in its time, a reasonable and even good idea. With the FDA not progressing the ANADs it was also a good move to continue with Rexista and Regabatin. Also the Odidis are well conntected in the pharma industry and with Della Penna there is a very capable CFO. IPCI is on a very good track. There will be the Rexista filling and as far as we know everything looks good.
Amigo, could you explain, what you are referring to with the sentences:
"IMO mgmt is rather poor at explaining why you need to own this stock and leaves out pieces of information."
And what are your reason for believien, "IMO, the recent move northward is reminiscent of an institutional trader."?
"Intellipharmaceutics Internation (NASDAQ:IPCI) Sellers Covered 5.97% of Their Shorts"
http://presstelegraph.com/2016/07/30/intellipharmaceutics-internation-nasdaqipci-sellers-covered-5-97-of-their-shorts/
Quote:
"IPCI’s total short interest was 1.06M shares in July as published by FINRA. Its down 5.97% from 1.13 million shares, reported previously. With 97,000 shares average volume, it will take short sellers 11 days to cover their IPCI’s short positions."
"IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) With the move up today (4.29%) on volume the stock may have put in a bottom, possibly a temporary bottom, but perhaps still a bottom. We need to get another up day with nice volume to solidify this as a bottom. Short-term technical indicators are suggesting bounce is likely to continue further and I believe we could see a rally up to $1.92-1.98 in the next sessions."
http://ac-investor.blogspot.co.il/2016/07/stocks-to-watch-for-july-28-2016.html
OxyContin® 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg 120mg prolonged release tablets
https://www.medicines.org.uk/emc/medicine/29384
"Intellipharmaceutics International (NASDAQ:IPCI) had its buy rating reiterated by analysts at Maxim Group. The analysts wrote, “We recently had lunch with CFO Domenic Della Penna.”"